Jeffrey D Chulay
- Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production methodJeffrey D Chulay
Applied Genetic Technologies Corporation, 11801 Research Drive, Alachua, FL 32615, USA
Hum Gene Ther 22:155-65. 2011..These results support continued development of rAAV-CB-hAAT for treatment of AAT deficiency...
- Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber CongenitJeffrey D Chulay; Fiscal Year: 2010..Efficacy will be measured by evaluation of visual fields, visual acuity and electroretinography. ..
- Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin DeficiencyJeffrey D Chulay; Fiscal Year: 2010..Results from this Phase 2 trial will be used to develop a Phase 3 study designed to satisfy the requirements for licensure of a gene therapy treatment for this orphan disease. ..